ISSN (online): 2250-141X Vol. 3 Issue 1, February 2013

SPECIATION AND ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF *ENTEROCOCCI* FROM A RURAL TERTIARY HEALTH CARE CENTER- A TWO YEARS STUDY.

Amit Singh^{1*}, Balram ji Omar¹, R C Pande¹, Ramakant Yadav², Amita Dohrae³

¹Department of Microbiology, UP Rural Institute of Medical Sciences and Research, Saifai, Etawah, India.

²Department of Neurology, UP Rural Institute of Medical Sciences and Research, Saifai, Etawah, India.

³Msc student, Department of Microbiology, Jiwaji University, Gwalior, M.P, India

*Corresponding Author-

Dr Amit Singh Assistant Professor Department of Microbiology UP Rural Institute of Medical Sciences and Research Saifai, Etawah, U.P -206310 dramitsingh.uprims@gmail.com, +91-9458641459

ABSTRACT

Aims: Enterococcus species are major nosocomial pathogen and are exhibiting vancomycin resistance with increasing frequency. Continuous monitoring and determination of antimicrobial susceptibility pattern is a necessity. The present study aims to determine the prevalence and susceptibility pattern of Enterococci in tertiary care hospital. Methods and Material: Total of 200 enterococcal strains isolated from various samples were identified and speciated by miniAPI(BioMeriux, France). Antibiotic susceptibility was determined for various drugs by Kirby bauer disc diffusion method. Results were interpreted as per CLSI guidelines and vancomycin MIC wasdetermined by Agar dilution method.

Results: 138 strains were E.faecalis, 52 were E.faeciumand 6 were E.avium and 4 were E.durans. High level resistance to penicillin, ampicillin, gentamicin and streptomycin were observed. Most (95%)of the strains were sensitive to linezolid.12% strains showed vancomycinresistance. Conclusions: High rate of resistance to penicillin and amino glycosides is observed in our tertiary care hospital and emergence of VRE has further worsened this situation. So, there is an urgent need for more rational and restricted use of antimicrobials.

Key words: Antimicrobial susceptibility, HLAR, VRE

Introduction

Speciation and antimicrobial susceptibility pattern of *Enterococci* from a rural tertiary health care center-A two years study.

Enterococci have attracted much attention in recent years due to their increased recognition as a cause of nosocomial infection patients in receiving antimicrobial agents. Serious enterococcal infections are often refractory to treatment and mortality is high. Infections by *Enterococci* have traditionally been treated with cell-wall active agents in combination with an aminoglycosides however emergence of high level resistance to aminoglycosides, β lactam antibiotics and to vancomycin by some strains together with association of HLAR with multidrug resistance has led to failure of synergistic effects of combination therapy. 1, 2, 3

Since the advent of VRE by Utley et al in 1988, enterococcal infections have been a cause of great concern among the health professionals. Therefore, VRE along with HLAR is making the treatment of such infections extremely difficult and pose a great challenge to clinicians.

Although 12 species in genus Enterococcus have been recognized, most common species is E.faecalisfollowed by E.faecium. E.faeciumpredominantly is more resistant species than *E.faecalis* and emergence of vancomycin resistance in it has caused an increase in frequency of its isolation.

The present study was undertaken considering the paucity of data on high level aminoglycoside resistance (HLAR) and Vancomycin resistance in enterococci, especially from a rural set —up and due the fact that enterococci are second leading cause of hospital acquired infection.

Material and method

Thepresent study was conducted fromOctober 2010 to October 2012, in the Department of Microbiology, UP Rural Institute of Medical Sciences and Research. Our hospital primarily caters to the rural population of western UP.Ethical clearance for the study was taken from Ethical Committee of the Institute.

A total of 200 enterococcal strains were isolated from various clinical samples (urine, blood, pus, high vaginal swab, ascetic fluid, bile) andidentified and speciated by biochemical tests [rapid ID 32 STREP (Mini API®BioMérieux SA, France)]. All isolates were stocked in duplicate for further testing.

Antibiotic susceptibility testing was done by Modified Kirby Bauer disc diffusion method using discs and Mueller Hinton agar as per CLSI guidelines. Various antibiotics tested were: Penicillin (10U/disc), Ampicillin (10µg), Tetracycline(30 µg), High

International Journal of Science & Technology www.ijst.co.in

gentamicin (120µg), High Strength Streptomycin $(300 \mu g)$, Strength Ciprofloxacin $(5\mu g)$, Vancomycin Teicoplanin $(30 \mu g)$, $(30 \mu g)$, Dalfopristin-Quinopristin (15 µg) and The Linezolid $(30\mu g)$. minimum inhibitory concentrations of Vancomycin were determined by Agar dilution method (range from 2µg /ml to 1024 µg /ml).

The source of media, antibiotic discs and Vancomycin powder were Hi- media ltd. Standard strains *E.faecalis*ATCC 29212 was used as control.

Results

A total 200 enterococcal isolateswere recovered from various clinical samples during the study period, of which, 138 strains were E.faecalis, were 52 E.faeciumand 6 were E.aviumand 4 were E.durans. The maximum numbers of isolates [91(45.5%)] were obtained from patients admitted to the intensive care units (ICUs), followed by surgical wards and medical wards (34.5%)] [40(20%)]. Antibiotic susceptibility tests showed high level resistance to various antibiotics tested. [Table 1] Most of the strains (95%) the strains were sensitive to linezolid. High-level aminoglycoside resistance (HLAR) to Gentamycin was shown by 102 (51%) and to Streptomycin by 94 (47%) enterococcal isolates respectively. Among glycopeptides, 92% Enterococci were sensitive to teicoplanin and 12% strains showed vancomycin resistance which were confirmed by Agar Dilution Test. The MIC of VRE ranged from 16-256µg/ml.

Discussion

Enterococci have become important nosocomial pathogens worldwide and are associated with a high mortality ¹⁻³. Further their infections poses a great challenge due to the inherent resistance of Enterococci to many antibiotics.

In the present study, *E.faecalis*(68%) was the predominant isolate followed by *E.faecium*(26%). Various studies done on Enterococci support the same findings.⁹

Beta-lactams along with aminoglycosides are considered as treatment of choice. Therefore resistance of Enterococci against these antibiotics has important clinical implications. Present study showed 69% and 66% resistance to Penicillin and Ampicillin respectively. Resistance to Penicillin may be due to low affinity penicillin binding proteins or due to production of β -lactamases.

In our study, HLAR was seen in 51% of the strains for Gentamicin (High Level) and 47% for Streptomycin (High level). 2] HLAR was more [Table E.faeciumthanE.faecalis. These finding also reported in some study. 10,12 HLAR in these strains can well nullify the efficacy combination therapy. Therefore, distinguishing HLAR from simple intrinsic resistance is important and should be adopted as a part of routine microbiology laboratory.

We, in this rural set up, found that the prevalence of HLAR among Enterococci to be lower than reported from urban

ISSN (online): 2250-141X Vol. 3 Issue 1, February 2013

hospitals.^{13, 16} Thereason for higher prevalence in urban hospitals could be because of the set up where chronic cases are prevalent and there is wider usage of broad spectrum antibiotics.

Present study showed 12% vancomycin resistance. 7.5% strains were 4.5% *E.faecalis* and were E.faecium.Results were also compared with Agar dilution method, which is based on MIC values. VanA (66.67%) and VanB(33.33%) phenotype were found to be predominant with MIC value 16-256µg/ml. Most (58.3%)of the VRE strains were isolated from urine, followed 16.67% each from blood and pus. Previously from India, there are few reports of emergence of VRE strains **MIC** with increased values. 12,13,14,15,17 [Table 5]. Most Isolates (95%) were sensitive to Linezolid. Amongst 24 5isolates were resistant to VRE. Linezolid. Linezolid can be considered as drug of choice to treat infections with VRE, however resistance to it has been

CONCLUSION

recommended.

High rate of resistance to penicillin and amino glycosides along with increased MIC values is observed in our tertiary care hospital and emergence of VRE strains has further worsened this situation. Prompt diagnosis and efficient infection control measures can restrict its spread. There is a need to study the antibiogram of enterococcal strains in order to minimize the selection and spread of such strains.

reported in many studies. 18,19,20 Hence

judicious use of Linezolid is highly

REFERENCES

- 1. Murray BE. The life and times of *Enterococci*. Clin Microbial Rev 1990; 3: 46 65.
- Jesudason MV, Pratima VL, PandianR, Abigail S. Characterisation of penicillin resistant *Enterococci*. Indian J Med Microbiol 1998; 16(1):16-8.
- 3. Patterson JE, Zervos M. High level gentamicin resistance in *Enterococcus*: microbiology, genetic basis and epidemiology. Rev Infect Dis. 1990; 12:644-51.
- 4. Mathur P, Kapil A, Chandra R et al. Antimicrobial resistance in *Enterococcus faecalis* at a tertiary care centre of northern India. Indian J Med Res. 2003; 118:25-8.
- 5. Utley A, Collins C, Naidoo J, George R.Vancomycin resistant *Enterococci*. Lancet 1988;i:57-8.
- 6. Rice LB. Emergence of vancomycin resistant *Enterococci*. Emerg Infect Dis 2001; 7: 183–187
- 7. Facklam RR, Collins MD. Identification of *Enterococcus* species isolated from human infections by a conventional test scheme. J ClinMicrobiol 1989; 27:731-4.
- 8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial

International Journal of Science & Technology www.ijst.co.in

ISSN (online): 2250-141X Vol. 3 Issue 1, February 2013

- susceptibility testing; 20th informational supplement. CLSI/NCCLS M100- S20. Wayne (PA). The Institute; 2010.
- 9. The gram positive cocci Part II: Streptococci, Enterococci and the "Streptococcus-like" bacteria, Chapter 12. In: Koneman EW, Allen SD, JandaWM, editors. Color Atlas and Textbook of Diagnostic Microbiology, 5thedn. New York: JB Lipincott; 1997.p 577-649
- 10. Bhat KG, Paul C, Bhat MG. Neonatal bacteremia due to high level aminoglycoside resistant (HLAR) *Enterococci*. Indian J Pediatr 1997; 64:537-9.
- 11. Miskeen PA, Deodhar L. Antimicrobial susceptibility pattern of *Enterococcus* species from Urinary Tract Infections. J Assoc Physicians India 2002; 50:378-81.
- 12. Taneja N, Rani P, Emmanuel R, Sharma M. Significance of vancomycin resistant *Enterococci* from urinary specimens at a tertiary care centre in northern India. Indian J Med Res 2004; 119:72-4.
- 13. Karmarkar MG, Gershom ES, Mehta PR. Enterococcal infections with special reference to phenotypic characterization and drug resistance. Indian J Med Res 2004; 119:22-5.
- 14. Kapoor L, Randhawa VS, Deb M. Antimicrobial resistance of

- enterococcal blood isolates at a pediatric care hospital in India. Jpn J Infect Dis 2005; 58:101-3.
- 15. Ghoshal U, Garg A, Tiwari DP, Ayyagiri A. Emerging vancomycin resistance in *Enterococci* in India. Indian J PatholMicrobiol2006; 49(4): 620-2.
- 16. Cetinkaya Y, Falk P, Mayhah CG. Vancomycin resistant Enterococcus. ClinMicrobiol Rev 2000; 13:686-707.
- 17. Shah L, Mulla S, Patel KG, Rewadiwala S.Prevalence of Enterococci with higher resistance level in a tertiary care hospital: A matter of great concern. Nat J Med Res 2012;2:25-7.
- 18. Gonzales, R. D., P. C. Schreckenberger, M. B. Graham, S. Kelkar, K. DenBesten, and J. P. Quinn.Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.2001; Lancet 357:1179.
- 19. Marshall, S. H., C. J. Donskey, R. Hutton-Thomas, R. A. Salata, and L. B. Rice. Gene dosage and linezolid resistance in *Enterococcus faecium* and *Enterococcus faecium* Agents Chemother.2002; 46:3334-36.
- Ruggero, K. A., L. K. Schroeder,
 P. C. Schreckenberger, A. S.
 Mankin, and J. P.
 Quinn. Nosocomial

International Journal of Science & Technology www.ijst.co.in

ISSN (online): 2250-141X Vol. 3 Issue 1, February 2013

superinfections due to linezolidresistant *Enterococcus faecalis*: evidence for a gene dosage effect on linezolid MICs. Diagn. Microbiol. Infect. Dis.2003; 47:511-513.

<u>**TABLE 1**</u>: Antimicrobial susceptibility pattern of Enterococci by modified Kirby Bauer Disc Diffusion Test

Antibiotic tested	% Sensitive	% Resistant
Penicillin	31	69
Ampicillin	34	66
Tetracycline	40	60
High Strength Gentamycin	49	51
High Strength Streptomycin	53	47
Erythromycin	19	81
Vancomycin	88	12
Teicoplanin	92	8
Linezolid	95	5
Dalfopristin-Quinopristin	85	15
Ciprofloxacin	13	87

Table 2: Frequency of HLAR among Enterococcus isolates

Specimen	Species	Total no. of isolates	High level resistance to Gentamycin	High level resistance to Streptomycin
Urine (n=136)	E.faecalis	100	33	31
	E.faecium	30	29	27
	Other spp	06	06	04
Blood (n=14)	E.faecalis	07	03	04
	E.faecium	07	06	05
	Other spp	00	00	00

ISSN (online): 2250-141X Vol. 3 Issue 1, February 2013

Other specimen	E.faecalis	31	08	06
(pus, vaginal	E.faecium	15	13	13
swab, bile,	Other spp	04	04	02
ascitic fluid)				
(n=50)				

<u>TABLE 3</u>
Total VRE isolation from different samples

Sample	Vancomycin	Vancomycin	No. of VRE
	resistant	resistant	
	E.faecalis	E.faecium	
Urine (n=136)	9	5	14
Blood (n=14)	2	2	4
Pus (n=22)	3	1	4
HVS (n=18)	0	0	0
Ascitic fluid (n=5)	1	1	2
Bile (n=5)	0	0	0
Total	15	9	24

<u>Table 4</u>. Characteristics of vancomycin resistant enterococci isolated in the present study

Isolate no.	Source	Icu/ward	Zone diameter (mm)/interpretation		MIC(μg/ml) Agar plate	Van phenotype
110.			Vancomycin	Tiecoplanin	test	phenotype
1		ICH	((D)	((D)	C 4	X
1	Urine	ICU	6 (R)	6 (R)	64	Van A
2	Urine	ICU	6 (R)	6 (R)	128	Van A
3	Blood	ICU	6 (R)	6 (R)	128	Van A
4	Urine	FSW	10 (R)	14 (S)	32	Van B
5	Urine	GW	10 (R)	8 (R)	64	Van A
6	Ascitic	ICU	6 (R)	14 (S)	16	Van B
	fluid					
7	Pus	MSW	10 (R)	8 (R)	64	Van A
8	Blood	NICU	10 (R)	10 (R)	32	Van A
9	Pus	ICU	8 (R)	8 (R)	128	Van A
10	Urine	MSW	8 (R)	8 (R)	64	Van A
11	Blood	ICU	6 (R)	6 (R)	256	Van A
12	Ascitic	ICU	10 (R)	16(S)	16	Van B
	Fluid					
13	Urine	ICU	10 (R)	14(S)	32	Van B
14	Urine	MMW	8 (R)	6 (R)	128	Van A
15	Urine	FSW	8 (R)	16(S)	64	Van B
16	Blood	NICU	6 (R)	14(S)	256	Van B
17	Urine	FSW	8 (R)	8 (R)	128	Van A
18	Pus	MSW	6 (R)	8 (R)	256	Van A

19	Urine	MMW	10(R)	18 (S)	16	Van B
20	Urine	ICU	8 (R)	10 (R)	64	Van A
21	Pus	MSW	6 (R)	8 (R)	128	Van A
22	Urine	GW	8 (R)	14(S)	64	Van B
23	Urine	ICU	6 (R)	16 (R)	256	Van A
24	Urine	ICU	6 (R)	8 (R)	256	Van A

ICU-Intensive Care Unit, NICU-Neonatal ICU, FSW-Female Surgical Ward, MSW-Male surgical Ward, MMW-Male Medical Ward, GW-Gyn&Obsward

Table 5. Comparison of VRE isolation from other studies

	Mathur et al	Karmaker et	Ghoshal et	Shah et al	Present study
	(2003)	al	al	(2011)	(2013)
		(2004)	(2006)		
Total	444	52	685	92	200
samples					
VRE(%)	5 (1%)	12 (23%)	10(1.4%)	8 (8%)	24(12%)
Positive	Blood(3),	Urine*,	Blood*,	Urine(5),	Urine(14)
samples	Urine(1),	Blood*, Pus*	Tissue*,	Blood(2),	Blood(4)
	soft		Urine*,	CSF(1)	Pus(4)
	tissue(1)		CVP tip*		Asciticfluid(2)
Phenotypes	Van A,VanB	VanB	Van A	Van A, Van	Van A, VanB
				В	
MIC (µg/ml)	16-512	>4	64-256	8-32	16-256

^{*} Sample size not mentioned